Registration number: 07598777

Claidmhor Pharma Ltd

Contents

Company Information	1
Abridged Balance Sheet	2 to 3
Notes to the Unaudited Abridged Financial Statements	4 to 8

Claidmhor Pharma Ltd

Company Information

Directors

Mr Michael John Dey Ms Laura Anne Dey Mrs Gail Alexandra Dey Eadaoin Brid McLoughlin

Registered office

3 Crewe Road Sandbach Cheshire CW11 4NE

Accountants

Knight Brown Chartered Certified Accountants 3 Crewe Road Sandbach Cheshire CW11 4NE

Claidmhor Pharma Ltd

(Registration number: 07598777)
Abridged Balance Sheet as at 31 May 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	4	35,021	41,201
Current assets
Debtors		55,019	207,868
Cash at bank and in hand		258,293	252,112
		313,312	459,980
Prepayments and accrued income		1,895	3,449
Creditors: Amounts falling due within one year		(247,334)	(390,160)
Net current assets		67,873	73,269
Total assets less current liabilities		102,894	114,470
Creditors: Amounts falling due after more than one year		(18,753)	(28,207)
Accruals and deferred income		(4,242)	(6,029)
Net assets		79,899	80,234
Capital and reserves
Called up share capital	5	100	100
Retained earnings		79,799	80,134
Shareholders' funds		79,899	80,234

For the financial year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 9 October 2025 and signed on its behalf by:
 

Claidmhor Pharma Ltd

(Registration number: 07598777)
Abridged Balance Sheet as at 31 May 2025

......................................... Mr Michael John Dey Director

Claidmhor Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2025

1	General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
3 Crewe Road
Sandbach
Cheshire
CW11 4NE
United Kingdom

The principal place of business is:
Linden Lea
Crewe Road
Sandbach
Cheshire
CW11 4RE
United Kingdom

These financial statements were authorised for issue by the Board on 9 October 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Claidmhor Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2025

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Fixtures and fittings	15% reducing balance
Motor vehicles	25% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Claidmhor Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 4 (2024 - 4).

Claidmhor Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2025

4	Tangible assets

	Furniture, fittings and equipment  £	Motor vehicles  £	Total £
Cost or valuation
At 1 June 2024	6,576	41,414	47,990
At 31 May 2025	6,576	41,414	47,990
Depreciation
At 1 June 2024	4,201	2,588	6,789
Charge for the year	356	5,824	6,180
At 31 May 2025	4,557	8,412	12,969
Carrying amount
At 31 May 2025	2,019	33,002	35,021
At 31 May 2024	2,375	38,826	41,201

5	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary A of £1 each	60	60	60	60
Ordinary B of £1 each	20	20	20	20
Ordinary C of £1 each	10	10	10	10
Ordinary D of £1 each	10	10	10	10
	100	100	100	100

6

Dividends

		2025		2024
		£		£
Interim dividend of £63,000.00 (2024 - £198,000.00) per ordinary share		63,000		198,000

Claidmhor Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2025

7	Related party transactions

Summary of transactions with parent

Mountain Heather Holdings Limited

Parent Entity Loan
During the year, net repayment were made to Mountain Heather Holdings Limited in the sum of £132,507.

At the balance sheet date, Mountain Heather Holdings Limited was owed £205,334 (2024: £337,841) in the form of a parent entity loan. This loan is interest free and repayable upon demand.

Summary of transactions with associates

Mountain Heather Hotel Ltd
Riverdon Rentals Ltd
Intercompany Loans

At the balance sheet date, the company was owed £2,223 (2024:£1,203) from <ountain Heather Hotel Ltd in the form of an intercompany loan. This loan is interest free and repayable upon demand.

At the balance sheet date, the company was owed £125 (2024:£NIL) from Riverdon Rentals Ltd in the form of an intercompany loan. This loan is interest free and repayable upon demand.

8	Parent and ultimate parent undertaking

The ultimate parent is Mountain Heather Holdings Ltd, incorporated in England & Wales.